Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later

Vaccine

Volumn 27, Issue 43, 2009, Pages 6048-6053

  Gilca, Vladimir ^a   De Serres, Gaston ^a   Boulianne, Nicole ^a   De Wals, Philippe ^a   Murphy, Donald ^b   Trudeau, Gisele ^c   Massé, Richard ^d   Duval, Bernard ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c Direction Régionale de Santé Publique de la Capitale Nationale   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Booster; Hepatitis B; Long term immunity; Vaccination

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ABSENCE OF SIDE EFFECTS; AGE DISTRIBUTION; ANAMNESIS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANADA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; VIRUS RESISTANCE;

ADOLESCENT; CHILD; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; KINETICS; MALE; QUEBEC; YOUNG ADULT;

EID: 70349296763     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.100     Document Type: Article

References (31)

1. Whittle H.C., Maine N., Pilkington J., Mendy M., Fortuin M., Bunn J., et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 345 (1995) 1089-1092
2. Da Villa G., Picciottoc L., Elia S., Peluso F., Montanaro F., and Maisto T. Hepatitis B vaccination: universal vaccination of newborn babies and children at 12 years of age versus high risk groups. A comparison in the field. Vaccine 13 13 (1995) 1240-1243
3. Van der Sande M.A., Waight P., Mendy M., Rayco-Solon P., Hutt P., Fulford T., et al. Long-term protection against carriage of hepatitis B virus after infant vaccination. J Infect Dis 193 11 (2006) 1528-1535
4. Shepard C.W., Finelli L., Fiore A.E., and Bell B.P. Epidemiology of hepatitis B and hepatitis B virus infection in United States children. Pediatr Infect Dis J 24 9 (2005) 755-760
5. Gilca V., Duval B., Boulianne N., Dion R., and De Serres G. Impact of the Quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program. Pediatr Infect Dis J 25 4 (2006) 372-374
6. Su F.H., Cheng S.H., Li C.Y., Chen J.D., Hsiao C.Y., Chien C.C., et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 25 47 (2007) 8085-8090
7. van der Sande M.A., Mendy M., Waight P., Doherty C., McConkey S.J., Hall A.J., et al. Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 25 8 (2007) 1509-1512
8. Salleras L., Dominguez A., Bruguera M., Cardenosa N., Batalla J., Carmona G., et al. Dramatic decline in acute hepatitis B infection and disease incidence rates among adolescents and young people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the schools of Catalonia (Spain). Vaccine 23 17-18 (2005) 2181-2184
9. Correll P.K., Hayen A., and Eyeson-Annan M. Hepatitis B immunisation in children aged 10-13 years in New South Wales, 2001. N S W Public Health Bull 14 1-2 (2003) 17-20
10. Heron L.G., Chant K.G., and Jalaludin B.B. A novel hepatitis B vaccination regimen for adolescents: two doses 12 months apart. Vaccine 20 (2002) 3472-3476
11. Hipgrave D.B., Maynard J.E., and Biggs B.A. Improving birth dose coverage of hepatitis B vaccine. Bull WHO 84 1 (2006) 65-71
12. Schaffner W., Gardner P., and Gross P.A. Hepatitis B immunization strategies: expanding the target. Ann Intern Med 118 4 (1993) 308-309
13. Poland G.A., and Jacobson R.M. Prevention of hepatitis B with the Hepatitis B Vaccine. N Engl J Med 351 27 (2004) 2832-2838
14. Young B.W., Lee S.S., Lim W.L., and Yeoh E.K. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat 10 1 (2003) 23-30
15. Minuk G., Ling N., Postl B., Waggoner J., Nicolle L., and Hoofnagle J. The changing epidemiology of hepatitis B virus infection in the Canadian north. Am J Epidemiol 121 (1985) 598-604
16. Patrick D.M., Bigham M., Ng H., White R., Tweed A., and Skowronski D.M. Elimination of acute hepatitis B among adolescents after one decade of an immunization program targeting Grade 6 students. Pediatr Infect Dis J 22 10 (2003) 874-877
17. Morris B.A.P., Harason P., and Butler-Jones D. Seroprevalence of hepatitis B in a small urban sexually transmitted disease clinic. Can J Public Health 83 1 (1992) 73-74
18. Dentinger C.M., McMahon B.J., Butler J.C., Dunaway C.E., Zanis C.L., Bulkow L.R., et al. Persistence of antibody to Hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 24 9 (2005) 786-792
19. Hassan S., and Ziba F. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine 25 17 (2007) 3511-3514
20. Su F.H., Chen J.D., Cheng S.H., Sung K.Y., Jeng J.J., and Chu F.Y. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat 15 1 (2008) 14-19
21. Hammitt L.L., Hennessy T.W., Fiore A.E., Zanis C., Hummel K.B., Dunaway E., et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 25 39-40 (2007) 6958-6964
22. Lin C.C., Chang C.K., Huang Y.L., and Tseng H.F. Low seroprevalence of hepatitis B surface antibody among nursing students in Taiwan: an implication for boosting. Vaccine 25 51 (2007) 8508-8511
23. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 120 2 (2007) pe373-pe381
24. Zanetti A.R., Mariano A., Romano L., D'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366 9494 (2005) 1379-1384
25. Gabbuti A., Romano L., Blanc P., Meacci F., Amendola A., Mele A., et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 25 16 (2007) 3129-3132
26. Diaz-Mitoma F., Law B., Subramanya A., and Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 26 14 (2008) 1759-1763
27. Duval B., Boulianne N., De Serres G., Laflamme N., De Wals P., Massé R., et al. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children. Vaccine 18 (2000) 1467-1472
28. European, Consensus, and Group. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565
29. Duval B., Gilca V., Boulianne N., De Wals P., Masse R., Trudeau G., et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 24 3 (2005) 213-218
30. Rapport taux d'incidence (par 100 000 personnes-années). Gouvernement du Québec, maladies à déclaration obligatoire - Capitale-Nationale. Accessible en ligne (page consultée le 26 mai 2009) [En ligne]. http://www.dspq.qc.ca/MADO/rapportIncPublic.asp?id=3.
31. Fitzsimons D., Francois G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 23 32 (2005) 4158-4166